![]() |
市場調查報告書
商品編碼
2085324
白內障手術器械市場:2026-2032年全球市場預測(按產品類型、技術、鏡片類型、應用和最終用戶分類)Cataract Surgery Devices Market by Product Type, Technology, Lens Type, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,白內障手術設備市場將成長至 149.3 億美元,複合年成長率為 8.36%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 85億美元 |
| 預計年份:2026年 | 91.8億美元 |
| 預測年份 2032 | 149.3億美元 |
| 複合年成長率 (%) | 8.36% |
在人口老化的今天,白內障手術設備在恢復視力方面發揮著至關重要的作用。白內障仍然是導致可預防性視力喪失的最主要原因之一。世界衛生組織(WHO)將白內障列為全球主要致盲原因之一,而根據國際防盲協會(IAPB)統計,超過1億人患有白內障引起的視力障礙。這使得對超音波乳化系統、人工人工水晶體黏彈性物質、手術顯微鏡、飛秒雷射平台、灌注和抽吸系統、眼科診斷設備以及一次性手術器械的需求持續旺盛。
白內障手術設備的市場趨勢正從以手術數量為主導、注重治療效果的眼科醫學模式。儘管超音波乳化術仍然是大多數白內障手術的全球標準,但創新主要集中在以下幾個方面:液體穩定性、能量調節、預裝人工水晶體輸送、散光矯正型和多焦點人工水晶體的性能、景深擴展型人工水晶體以及手術規劃軟體。這些改進旨在減少內皮細胞流失、提高屈光精度、輔助散光矯正並縮短手術時間。
人工智慧 (AI) 正開始影響白內障手術設備,並滲透到患者護理的整體流程中,尤其是在篩檢、診斷、生物特徵數據解讀、人工水晶體(IOL) 度數選擇以及手術室工作流程管理方面。 AI 影像分析有助於識別白內障的嚴重程度、合併的視網膜疾病、眼表狀況以及可能影響手術方案的角膜不規則情況。在高階白內障手術中,研究人員正在評估機器學習模型,透過整合眼軸長度、角膜曲率、前房深度、水晶體厚度、後角膜曲率、手術史以及真實的術後結果,來提高屈光結果預測的準確性。
亞太地區人口老化、白內障高發以及中國、印度、日本、韓國、澳洲和都市區等國家眼科醫療基礎設施的不斷完善,使其擁有巨大的長期手術發展機會。大規模白內障手術計畫、國家防盲舉措以及私立眼科醫院網路正在推動對超聲乳化系統、價格適中的單人工水晶體人工水晶體、眼科黏彈性物質以及城市地區日益成長的高階人工水晶體的需求。該地區醫療資源分配也存在顯著差異,先進的屈光白內障手術集中在大都會圈,而基礎白內障治療在醫療服務不足的地區仍是首要任務。
在東協市場,私人醫療網路的擴張、中產階級需求的成長、區域眼科保健舉措以及促進白內障篩檢和手術轉診的醫療旅遊路線,都在推動市場發展。在新加坡、泰國、馬來西亞、印尼、越南和菲律賓,對各種醫療設備的需求都很旺盛,從經濟實惠的超音波乳化平台、單焦點人工人工水晶體和可重複使用的手術器械,到高階水晶體、先進的生物辨識技術和飛秒雷射白內障手術,應有盡有。醫療器材的普及趨勢仍與價格負擔能力、外科醫師的訓練水準、保險報銷情況以及都市區醫療資源分配不均密切相關。
由於美國手術量大、門診手術中心普及率高、先進診斷技術應用廣泛,以及患者自費購買老花眼矯正和散光矯正型人工水晶體,美國仍是白內障手術設備的標竿。加拿大的特點是公共醫療保健系統、准入管理、省級採購政策以及對成熟技術的持續應用。墨西哥和巴西是拉丁美洲的關鍵市場,這兩個國家公共白內障防治宣傳活動與私人高階手術的成長並存,從而催生了對可靠的Faco系統、價格適中的人工水晶體和高效耗材的需求。
行業領導企業應根據高階屈光白內障手術和大批量基礎白內障治療的需求,調整產品系列。均衡的策略應包括可靠的Faco平台、預裝單焦點和散光人工水晶體、高階老花眼矯正鏡片、眼科黏彈性物質、高效的一次性產品以及基於軟體的術前規劃工具。透過培訓、保障服務運轉率、提供實證臨床教育以及最佳化手術流程來支持外科醫生的機構,更有可能贏得客戶的長期忠誠。
本執行摘要是基於公共衛生、監管、臨床實踐和產業等領域權威資訊來源的二手研究。主要資料來源包括世界衛生組織(WHO)、國際防盲協會(IAPB)、各國衛生機構、同儕審查的眼科文獻、醫療設備法規結構、臨床實務指南、以及公開的保險報銷和採購資訊。
受人口老化、減少可預防性失明計劃以及術後視覺品質日益成長的期望等因素推動,白內障手術設備市場預計將持續擴張。創新正從手術顯微鏡和微創手術器械發展成為一個涵蓋診斷、人工水晶體(IOL)選擇、手術計劃、水晶體植入、術中導航和術後追蹤的綜合生態系統。
The Cataract Surgery Devices Market is projected to grow by USD 14.93 billion at a CAGR of 8.36% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 8.50 billion |
| Estimated Year [2026] | USD 9.18 billion |
| Forecast Year [2032] | USD 14.93 billion |
| CAGR (%) | 8.36% |
Cataract surgery devices are central to restoring vision in an aging world, where cataract remains one of the most important causes of avoidable vision impairment. The World Health Organization identifies cataract as a leading cause of blindness globally, while the International Agency for the Prevention of Blindness reports that more than 100 million people live with vision loss attributable to cataract. This creates sustained demand for phacoemulsification systems, intraocular lenses, ophthalmic viscoelastic devices, surgical microscopes, femtosecond laser platforms, irrigation and aspiration systems, ophthalmic diagnostic equipment, and disposable surgical instruments.
Market growth is being shaped by demographic aging, rising diabetes prevalence, improved access to ophthalmic care, and greater patient expectations for spectacle independence after surgery. Premium intraocular lenses, preloaded IOL delivery systems, enhanced biometry, small-incision techniques, and safer fluidics are helping providers improve outcomes while addressing high procedure volumes. For manufacturers, competitive advantage increasingly depends on clinical evidence, surgeon training, device reliability, reimbursement alignment, regulatory compliance, and the ability to support efficient ambulatory and hospital-based cataract surgery workflows.
The cataract surgery devices landscape is shifting from volume-driven surgical supply toward digitally enabled, outcomes-focused eye care. Phacoemulsification remains the global standard for most cataract procedures, but innovation is concentrated around fluidics stability, energy modulation, preloaded lens delivery, toric and multifocal IOL performance, extended-depth-of-focus lenses, and surgical planning software. These improvements are designed to reduce endothelial cell loss, improve refractive predictability, support astigmatism correction, and shorten operating room time.
Another major shift is the migration of cataract surgery into high-throughput outpatient settings. In developed markets, ambulatory surgery centers and day-care ophthalmology units are emphasizing standardization, compact equipment, validated sterilization processes, and disposable kits to improve throughput and infection control. In emerging markets, government blindness-prevention programs and private hospital networks are expanding access, creating demand for durable, cost-effective cataract surgery devices that can support large surgical volumes without compromising safety, traceability, or clinical quality.
Artificial intelligence is beginning to influence cataract surgery devices across the patient pathway, especially in screening, diagnostics, biometry interpretation, IOL power selection, and operating room workflow management. AI-supported image analysis can help identify cataract severity, coexisting retinal disease, ocular surface factors, and corneal irregularities that may affect surgical planning. In premium cataract procedures, machine learning models are being evaluated to improve refractive outcome prediction by incorporating axial length, keratometry, anterior chamber depth, lens thickness, posterior corneal curvature, surgical history, and real-world post-operative outcomes.
The near-term impact of AI is expected to be decision support rather than autonomous surgery. Device manufacturers and providers are using AI to reduce planning variability, optimize intraocular lens inventory, forecast surgical demand, improve patient triage, and strengthen post-operative monitoring. Adoption will depend on transparent validation, regulatory clearance, data privacy controls, cybersecurity, bias monitoring, and integration with electronic health records, optical biometers, imaging platforms, surgical microscopes, and cataract surgery planning ecosystems.
Asia-Pacific represents a major long-term procedural opportunity due to population aging, high cataract burden, and expanding ophthalmology infrastructure across China, India, Japan, South Korea, Australia, and Southeast Asia. High-volume cataract surgery programs, national blindness-prevention initiatives, and private eye hospital networks are driving demand for phacoemulsification systems, affordable monofocal IOLs, ophthalmic viscoelastic devices, and increasingly premium intraocular lenses in urban centers. The region also reflects wide variation in access, with advanced refractive cataract surgery concentrated in metropolitan markets and essential cataract care remaining a priority in underserved areas.
North America is characterized by advanced surgical adoption, strong demand for premium IOLs, established ambulatory surgery centers, and robust use of optical biometry, digital planning, and electronic workflow tools. Europe benefits from universal or mixed reimbursement systems, strict regulatory expectations under the EU Medical Device Regulation, and a strong clinical base for toric, multifocal, and extended-depth-of-focus IOL adoption. Latin America continues to expand through public-private eye care programs, with Brazil and Mexico serving as key procedural hubs where affordability, procurement efficiency, and private-sector premium surgery shape device demand.
The Middle East is investing in specialty hospitals, medical tourism, and modern ophthalmic platforms, particularly across Gulf economies where advanced diagnostics and premium cataract surgery are increasingly available. Africa remains highly access-driven, where cataract surgical coverage, affordability, workforce availability, surgical outreach, and durable equipment supply are decisive to reducing avoidable blindness. Across all regions, demand is linked to aging demographics, diabetes-related eye disease, avoidable blindness initiatives, surgeon training, and the ability of manufacturers to balance premium innovation with accessible pricing and reliable service support.
ASEAN markets are benefiting from expanding private healthcare networks, growing middle-class demand, regional eye health initiatives, and medical tourism corridors that improve cataract screening and surgical referrals. Device demand ranges from cost-efficient phaco platforms, monofocal IOLs, and reusable surgical instruments to premium lenses, advanced biometry, and femtosecond laser-assisted cataract surgery in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Adoption patterns remain linked to affordability, surgeon training, reimbursement availability, and urban-rural access gaps.
The GCC is distinguished by high healthcare investment, medical tourism ambitions, and rapid adoption of advanced ophthalmic technologies, including premium IOLs, femtosecond laser-assisted cataract surgery, digital diagnostics, and integrated surgical planning systems. The European Union remains a rigorous but attractive market, where compliance with the EU Medical Device Regulation, clinical evidence, vigilance reporting, and post-market surveillance are essential to device commercialization. In this environment, cataract surgery device suppliers must demonstrate safety, performance, traceability, and long-term clinical value.
BRICS economies combine high disease burden with large-scale health system modernization, making them pivotal for high-volume cataract care, local manufacturing strategies, and broader access to ophthalmic devices. G7 countries represent mature, innovation-led markets with strong adoption of advanced biometry, premium IOLs, outpatient surgical workflows, and evidence-based reimbursement assessment. NATO countries overlap significantly with high-income European and North American markets, where supply chain resilience, cybersecurity for connected ophthalmic devices, data protection, and regulatory compliance are increasingly important procurement considerations.
The United States remains a benchmark cataract surgery device market due to high procedure volumes, strong ambulatory surgery center penetration, advanced diagnostic adoption, and patient-paid demand for presbyopia-correcting and toric IOLs. Canada is shaped by publicly funded care, access management, provincial procurement policies, and steady adoption of proven technology. Mexico and Brazil are important Latin American markets where public cataract campaigns coexist with private premium surgery growth, creating demand for reliable phaco systems, affordable IOLs, and efficient consumable supply.
In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain established cataract surgery systems with increasing emphasis on waiting-list management, operating room efficiency, refractive outcomes, and regulatory evidence. Germany is notable for advanced ophthalmic technology adoption and clinical specialization, while the United Kingdom continues to prioritize cost-effective outpatient delivery and service capacity. France, Italy, and Spain combine strong public ophthalmology systems with private-sector demand for premium intraocular lenses. Russia presents demand from an aging population, but procurement conditions, regulatory pathways, currency volatility, and supply continuity require careful risk management.
China and India are the largest cataract opportunity centers by population scale, with demand spanning high-volume affordable surgery, government and charitable access programs, domestic manufacturing, and premium urban eye care. Japan has an advanced aging demographic, strong quality expectations, and sophisticated adoption of modern diagnostics and IOL technologies. Australia and South Korea show high use of optical biometry, premium IOLs, minimally invasive workflows, and digitally supported surgical planning, making them influential Asia-Pacific markets for innovation-led cataract surgery devices and clinical best practices.
Industry leaders should align portfolios with both premium refractive cataract surgery and high-volume essential cataract care. A balanced strategy should include reliable phaco platforms, preloaded monofocal and toric IOLs, premium presbyopia-correcting lenses, ophthalmic viscoelastic devices, efficient disposables, and software-enabled planning tools. Organizations that support surgeons with training, service uptime, evidence-based clinical education, and procedure workflow optimization are better positioned to earn long-term loyalty.
Manufacturers should also prioritize AI-ready data infrastructure, interoperable device ecosystems, cybersecurity-by-design, and post-market evidence generation. Regional strategies must reflect reimbursement realities, procurement cycles, regulatory timelines, clinical guideline adoption, and affordability. In emerging markets, partnerships with eye hospitals, nongovernmental blindness-prevention programs, training institutions, and local distributors can expand access, while in mature markets differentiation should focus on refractive precision, workflow efficiency, safety, sustainability, and patient-reported outcomes.
This executive summary is based on secondary research from recognized public health, regulatory, clinical, and industry sources. Key reference points include the World Health Organization, International Agency for the Prevention of Blindness, national health agencies, peer-reviewed ophthalmology literature, medical device regulatory frameworks, clinical practice guidelines, and publicly available reimbursement and procurement information.
The analysis evaluates cataract disease burden, demographic trends, surgical workflow evolution, device adoption patterns, regional access dynamics, regulatory requirements, and technology innovation. Insights were synthesized through triangulation of epidemiological evidence, procedure drivers, clinical evidence, regulatory conditions, reimbursement structures, and commercial indicators to provide a practical view of cataract surgery devices without relying on unverified claims, market sizing, market share estimates, or forecasts.
The cataract surgery devices market is positioned for sustained expansion as population aging, avoidable blindness reduction programs, and rising expectations for post-surgical visual quality converge. Innovation is moving beyond the operating microscope and phaco machine toward an integrated ecosystem of diagnostics, IOL selection, surgical planning, lens delivery, intraoperative guidance, and outcome tracking.
Device leaders that combine clinical reliability, digital intelligence, regulatory discipline, and region-specific access strategies will be best placed to capture growth. The market's next phase will reward organizations that improve surgical efficiency, refractive predictability, affordability, interoperability, and patient-centered outcomes across both mature and emerging eye care systems.